Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10338250 | 0.86 | MEN1 (0.46) | MEN1KMT2AHTTL3MBTL1CYP2C19 | |
| SCHEMBL250885 | 0.83 | CES1 (0.53) | MEN1KMT2AHTTL3MBTL1CYP2C19 | |
| SCHEMBL24193442 | 0.80 | MEN1 (0.47) | MEN1KMT2AHTTL3MBTL1CYP2C19 | |
| SCHEMBL6648152 | 0.79 | MEN1 (0.50) | MEN1KMT2AHTTL3MBTL1CYP2C19 | |
| SCHEMBL1877690 | 0.76 | KMT2A (0.51) | MEN1KMT2AHTTL3MBTL1CYP2C19 | |
| SCHEMBL6682858 | 0.76 | LMNA (0.53) | MEN1KMT2AHTTNPC1RAB9A | |
| SCHEMBL5007991 | 0.75 | MTOR (0.47) | MEN1KMT2AHTTL3MBTL1CYP2C19 | |
| Hydrochloric Acid SCHEMBL8251166 | 0.74 | SMN1; SMN2 (0.41) | MEN1KMT2AHTTL3MBTL1CYP2C19 | |
| SCHEMBL25380127 | 0.74 | LPAR1 (0.47) | MEN1KMT2AHTTCYP2C19LMNA | |
| SCHEMBL10782311 | 0.74 | NPC1 (0.48) | MEN1KMT2ANPC1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468378-B2 | Substituted quinoline compounds | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| US-20050234099-A1 | Substituted quinoline compounds | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234099-A1 | Substituted quinoline compounds | APOB, APOL1, MTPN | MEN1 1437/4885KMT2A 3968/4885HTT 526/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | MEN1 1637/4885KMT2A 4384/4885HTT 798/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | MEN1 1637/4885KMT2A 4384/4885HTT 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.